Trial will evaluate the safety and effectiveness of the AtriCure Isolator® Synergy™ EnCompass® clamp and AtriClip® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset atrial ...
Management highlighted Q1 2026 revenue growth and improved profitability while keeping full-year guidance unchanged, and positioned the accelerated BoxX-NoAF enrollment timeline—now expected to ...
Full-year 2026 revenue guidance of $600 million to $610 million assumes continued strength in pain management, appendage ...
Investing.com - Piper Sandler has reiterated an Overweight rating and $50.00 price target on AtriCure Inc. (NASDAQ:ATRC), highlighting the potential of the company’s BoxX-NoAF clinical trial.
Hosted on MSN
AtriCure reiterates 2026 revenue $600M-$610M as BoxX-NoAF enrollment targets year-end completion
"AtriCure is off to a strong start in 2026 with worldwide revenue of $140 million in the first quarter, reflecting 14% growth year-over-year." (CEO, President & Director Michael H. Carrel) "Beyond our ...
AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results